DanCann Pharma A/S is strengthening its regulatory focus by appointing a life science lawyer to the board of directors

Copenhagen, Denmark, May 12, 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma" or "the Company"), a Danish company powered by cannabinoids, hereby announces the nomination of Louise Bertelsen Forman to join the board of directors at the upcoming annual general meeting on May 30, 2023.

Louise Bertelsen Forman is an equity partner and attorney at the law firm Loeven, which specializes in the life science field. With over 10 years of experience in the industry, Louise is known for her "can-do attitude" and extensive industry knowledge, which has led to impressive results and a position as one of the leading lawyers in the life science field in Denmark. Louise is a board member of Life Science Law DK and Loeven Advokatfirma, and in addition to her legal career, she has experience from her previous role as an attorney in Corporate Legal Life Science & Business Development at H. Lundbeck A/S.

Louise characterizes herself as having an interest in science and healthcare, as well as a strong value-driven mindset. She is motivated to collaborate with companies that work to revolutionize areas of disease and make a difference for patients.

Privately, Louise is married and has two children, and comes from a family of pharmacists and pharmacy owners with roots in Funen and West Jutland.

At the end of last year, DanCann Pharma received approval for its facilities in Ansager and is rapidly approaching its commercial breakthrough after the EU-GMP certification of Biotech Pharm1. With the future DanCann Pharma is facing, it has been a priority for the Company to further strengthen its regulatory focus.

Carsten Trads, Chairman of DanCann Pharma, comments:

• The future for DanCann Pharma looks promising as the Pilot Programme for the manufacturing of medicinal cannabis has become permanent in Denmark. The Company has invested significantly in production facilities that are "fit for purpose" and wants to launch more products and optimize and maximize the value of their existing products. There will be a strong focus on market access and brand maximization in Denmark and Europe in the near future.

• As the company enters the market, its competencies and skills in the regulatory aspects become increasingly relevant. And here, Louise brings unique competencies and industry knowledge that will be a big asset in the board.

Louise Bertelsen Forman says:

• The cannabis industry has been a field of growth and has attracted significant attention since the inception of the Pilot Programme. DanCann Pharma is considered one of the pioneers here at home and is in an exciting place with a well-managed team, a GMP-approved production, and products that are maturing and increasing in the market. With the expectations that DanCann Pharma has for the future, the regulatory focus will be central, and I look forward to contributing to the Company's growth with my experience from established pharmaceutical companies and biotech companies.

Jeppe Krog Rasmussen, CEO of DanCann Pharma, concludes:

• DanCann Pharma's ultimate goal is to establish a sustainable business that can make a difference for the patient groups that the company serves. To reach more relevant patients, we as an industry have an obligation to support increased clinical experience and to increase the evidence base. It is also important that we closely follow political processes and contribute our expertise. Since Louise has extensive experience with these matters, I have great confidence that she, as part of the upcoming board, will be able to contribute to this work.

The Company will hold its annual general meeting on May 30, 2023, where Louise is running for the board of directors in DanCann Pharma.

About DanCann Pharma A/S

DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company.

The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma is EU-GMP-approved by the Danish Medicines Agency under the Danish Pilot Programme for medical cannabis, and have, among other things, license for manufacturing, export, import and distribution. The DanCann Pharma group also owns the subsidiary CannGros ApS, which is the market leader in Denmark with the import and distribution of the products Bedrocan®, Bedica® and Bediol® to all the Danish pharmacies.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm and side listed on OTCQB Venture Market in USA (OTCQB: DCPXF).

For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO

Phone: +45 2963 6920

E-mail: [email protected]

Forward-looking-statement:

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.